MarketPulse
G

$GLPG

3 articles found
2 positive
0 negative
1 neutral
BenzingaBenzinga··Vandana Singh

Gilead Bolsters Inflammation Arsenal With $1.675B Ouro Medicines Deal

Gilead acquires Ouro Medicines for $1.675B upfront, targeting inflammation pipeline expansion. Galapagos NV partners to co-develop lead asset OM336.
GILDACLXGLPGacquisitionorphan drug designation
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Galapagos, Gilead in Advanced Talks on T-Cell Therapy Partnership

Galapagos and Gilead are in advanced partnership talks for a first-in-class T-cell engager for autoimmune diseases, with 50% cost-sharing and €500 million capital freed for Galapagos.
GILDGLPGstrategic partnershipclinical development
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Galapagos and Gilead Team Up on Breakthrough T Cell Engager for Autoimmune Diseases

Galapagos and Gilead plan to jointly develop an Ouro T cell engager for autoimmune diseases, splitting acquisition costs while Galapagos leads development and Gilead commercializes, freeing $500M in Galapagos cash.
GILDGLPGautoimmune diseasesorphan drug designation